Glycoxidative profile of cancer patient serum: A clinical result to associate glycation to cancer.
The influence of advanced glycation end products (AGEs) in the biological processes contribute to the life changing complications such as progression of cancer, diabetes and other chronic disorder. The receptor of AGEs while interacting with its ligands causes a never ending irregularity in the cell signaling communication. Hence, AGEs is considered as an important link between progression and contribution to cancer. This study focuses on the presence and/or absence of oxidative and glycative stress in the serum samples of various cancer patients. During analysis of the early and intermediate glycation product in cancer patient's sera, our result indicates an increasing trend of both the adducts as compared to normal healthy subjects (NHS). Similarly, one of the AGEs i.e., carboxymethyllysine (CML) was found to be enhanced in cancer sera as compared to NHS. The binding characteristics of circulating auto-antibodies in cancer patient's sera against HSA-AGEs were assessed through ELISA and further, the maximum percent inhibition against HSA-AGEs was observed as 57-63%, 46-62% and 42-64% in prostate cancer, lung cancer and head & neck cancer. Hence our result successfully assisted the presence of AGEs in all the cancer patient's sera though it is not clear which specific cancer is more potent to AGEs.